Targeting resistant clones and cancer stem cells is a challenging task, as CSC markers (including CD133, CD44, and ALDH) are not exclusively expressed by these cells’ sub-populations, and wide phenotype variability exists among CSCs from different patients and also within the same tumor. Here, CD44 is linked to neoplasm.